PP
EW icon

Palladium Partners’s Edwards Lifesciences EW Stock Holding History

Palladium Partners’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-1,920
Closed -$22K – 571
2013
Q2 		$22K Buy
+1,920
New +$22.7K ﹤0.01% 413

Other funds holding EW

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Palladium Partners's EW Position: Q3 2013 in Review

Palladium Partners sold out of Edwards Lifesciences (EW) in Q3 2013, closing a stake of 1,920 shares — an estimated $22K sold.

Palladium Partners first reported a position in EW in Q2 2013 and held it in 1 quarter. The position peaked at $22K in Q2 2013. 409 funds tracked by Wall St. Rank hold EW as of Q3 2013.

  • Palladium Partners reported no remaining Edwards Lifesciences position as of Q3 2013 after selling out during the quarter.
  • Palladium Partners sold 1,920 Edwards Lifesciences shares in Q3 2013, an estimated $22K.
  • Palladium Partners first reported a position in Edwards Lifesciences in Q2 2013 and held it in 1 quarter.
  • Palladium Partners's Edwards Lifesciences position peaked at $22K in Q2 2013.
  • 409 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2013.

Based on Palladium Partners's 13F filing for Q3 2013, filed 24 Oct 2013.